Antipsychotics for primary alcohol dependence: A systematic review and meta-analysis of placebo-controlled trials

Journal of Clinical Psychiatry

Volumn 74, Issue 7, 2013, Pages

  Kishi, Taro ^a,b   Sevy, Serge ^c   Chekuri, Raja ^b   Correll, Christoph U ^b,d,e,f  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Northwell Health   (United States)

^c NEW YORK INSTITUTE OF TECHNOLOGY   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^f DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; BLONANSERIN; CEFSULODIN; CHLORPROMAZINE; CLOTIAPINE; CLOZAPINE; FLUPENTIXOL DECANOATE; ILOPERIDONE; LOXAPINE; LURASIDONE; MESORIDAZINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PEROSPIRONE; PERPHENAZINE; PLACEBO; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; SULPIRIDE; THIORIDAZINE; TIAPRIDE; TIOTIXENE; UNINDEXED DRUG; ZIPRASIDONE;

ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; ANXIETY; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; DROWSINESS; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; HUMAN; INCREASED APPETITE; INSOMNIA; META ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SKIN TOXICITY; SYSTEMATIC REVIEW; TREATMENT DURATION; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 84880967051     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12r08178     Document Type: Article

References (53)

1. Merikangas KR, McClair VL. Epidemiology of substance use disorders. Hum Genet. 2012;131(6):779-789.
2. Swendsen J, Burstein M, Case B, et al. Use and abuse of alcohol and Rlicit drugs in US adolescents: results of the National Comorbidity Survey Adolescent Supplement. Arch Gen Psychiatry. 2012;69(4):390-398.
3. Centers for Disease Control and Prevention (CDC). Alcohol attributable deaths and years of potential life lost United States, 2001. MMWR Morb Mortal Wkly Rep. 2004;53(37):866-870.
4. Mokdad AH, Marks JS, Stroup DF, et al. Actual causes of death in the United States, 2000. JAMA. 2004;291(10):1238-1245.
5. Rivara FP, Garrison MM, Ebel B, et al. Mortality attributable to harmful drinking in the United States, 2000.J-Stud Alcohol. 2004;65(4):530-536.
6. Holder HD, Gruenewald PJ, Ponicki WR, et al. Effect of community based interventions on high risk drinking and alcohol related injuries. JAMA. 2000;284(18):2341-2347.
7. Treno AJ, Parker RN, Holder HD. Understanding US alcohol consumption with social and economic factors: a multivariate time series analysis, 1950-1986.J Stud Alcohol. 1993;54(2):146-156.
8. Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol. 2008;75(1):34-56.
9. Everitt BJ, Hutcheson DM, Ersche KD, et al. The orbital prefrontal cortex and drug addiction in laboratory animals and humans. Ann N YAcad Sd. 2007;1121(1):576-597.
10. Hutchison KE. Alcohol dependence: neuroimaging and the development of translational phenotypes. Alcohol Cliii Exp Res. 200X;32-(7) 1111-1112.
11. Perra S, Clements MA, Bernier BE, et al. In vivo ethanol experience increases D2-autoinhibition in the ventral tegmental area. Neuropsychopharmacology. 2011;36(5):993-1002.
12. Goldstein RZ, Tomasi D, Alia Klein N, et al. Dopaminergic response to drug words in cocaine addiction. J Neurosci. 2009;29(18):6001-6006.
13. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35(1):217-238.
14. Koob GF, Kenneth Lloyd G, Mason BJ. Development of pharmacotherapies for drug addiction: a Rosetta stone approach. Nat Rev Drug Discov. 2009;8(6):500-515.
15. Myrick H, Li X, Randall PK, et al. The effect of aripiprazole on cue induced brain activation and drinking parameters in alcoholics. J Clin Psychopharmacol. 20-10;30(4):365-372.
16. Martinez D, Gil R, Slifstein M, et al. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry. 2005;58(10):779-786.
17. Depping AM, Komossa K, Kissling W, et al. Second generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010;(12) :CDOO8120.
18. Komossa K, Depping AM, Meyer M, et al. Second generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev. 20-10; (12): CD008141.
19. Komossa K, Depping AM, Gaudchau A, et al. Second generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev. 2010;(12):CD008121.
20. Kampman KM, Pettinati HM, Lynch KG, et al. A double blind, placebo controlled pilot trial of quetiapine for the treatment of type A and type B alcoholism. J Clin Psychopharmacol. 2007;27(4):344-351.
21. Hutchison KE, Ray L, Sandman E, et al. The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology. 2006;3-1(6): 1310-1317.
22. Guardia J, Segura L, Gonzalvo B, et al. A double blind, placebo controlled study of olanzapine in the treatment of alcohol dependence disorder. Alcohol Clin Exp Res. 2004;28(5):736-745.
23. Litten RZ, Fertig JB, Falk DE, et al; NCIG 00J-Study Group. A double blind, placebo controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy drinking alcohol dependent patients. Alcohol Clin Exp Res. 2012;36(3):406-416.
24. Ray LA, Chin PF, Heydari A, et al. A human laboratory study of the effects of quetiapine on subjective intoxication and alcohol craving. Psychopharmacology (Berl). 201-1;2-17(3)341-351.
25. Wiesbeck GA, Weijers HG, Lesch OM, et al. Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo controlled study. Alcohol Alcohol. 200-1;36(4) :329-334.
26. Marra D, Warot D, Berlin I, et al. Amisulpride does not prevent relapse in primary alcohol dependence: results of a pilot randomized, placebo controlled trial. Alcohol Clin Exp Res. 2002;26(10):1545-1552.
27. Shaw GK, Majumdar SK, Waller S, et al. Tiapride in the long term management of alcoholics of anxious or depressive temperament. Br J Psychiatry. 1987;150(2):164-168.
28. Shaw GK, Waller S, Majumdar SK, et al. Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry. 1994;165(4):515-523.
29. BenderS, Scherbaum N, Soyka M, et al. The efficacy of the dopamine D2/D3-antagonist tiapride in maintaining abstinence: a randomized, double blind, placebo controlled trial in 299-alcohol dependent patients. Int J Neuropsychopharmacol. 2007;10(5) :653-660.
30. Anton hF, Kranzler H, Breder C, et al. A randomized, multicenter, double blind, placebo controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol. 2008;28(1): 5-12.
31. Cohn LD, Becker BJ. How meta analysis increases statistical power. Psychol Methods. 2003;8(3):243-253.
32. Correll CU, Sheridan EM, DelBello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo controlled trials. BipolarDisord. 2010;12(2):116-141.
33. Farahani A, Correll CU. Are antipsychotics or antidepressants needed for psychotic depression? a systematic review and meta analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry. 2012;73(4):486-496.
34. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta analysis of placebo controlled randomized trials. Am J Psychiatry. 2009;166(9):980-991.
35. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta analysis. Lancet. 2012;379(9831):2063-2071.
36. Anton hF, Moak DH, Latham P. The Obsessive Compulsive Drinking Scale: a self rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 1995;19(1):92-99.
37. Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res. 1999;23(8):1289-1295.
38. DerSimonian R, Laird N. Meta analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
39. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta analyses. BMJ. 2003;327(7414) :557-560.
40. Guardia J, Roncero C, Galan J, et al. A double blind, placebo controlled, randomized pilot study comparing quetiapine with placebo, associated to naltrexone, in the treatment of alcohol dependent patients. Addict Behav. 2011;36(3):265-269.
41. Baltieri DA, Daró FR, Ribeiro PL, et al. The role of alcoholic beverage preference in the severity of alcohol dependence and adherence to the treatment. Alcohol. 2009;43(3): 185-195.
42. Velligan DI, Weiden PJ, Sajatovic M, et al; Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Rlness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental Rlness. J Clin Psychiatry. 2009;70(suppl 4):1-46, quiz 47-48.
43. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25(suppl 2):512-S21.
44. Rubio G, Martinez I, Ponce G, et al. Long acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry. 2006;51(8):531-539.
45. Loebl T, Angarita GA, Pachas GN, et al. A randomized, double blind, placebo controlled trial of long acting risperidone in cocaine dependent men. J Clin Psychiatry. 2008;69(3):480-486.
46. Stedman M, Pettinati HM, Brown ES, et al. A double blind, placebo controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence. Alcohol ClinExpRes. 2010;34(10):1822-1831.
47. Brown ES, Garza M, Carmody TJ. A randomized, double blind, placebo controlled add on trial of quetiapine in outpatients with bipolar disorder and alcohol use disorders. J Clin Psychiatry. 2008;69(5):701-705.
48. Green Al, Burgess ES, Dawson R, et al. Alcohol and cannabis use in schizophrenia: effects of clozapine vs risperidone. Schi zophr Res. 2003;60(1): xi x5.
49. Brunette MF, Drake RE, Xie H, et al. Clozapine use and relapses of substance use disorder among patients with co occurring schizophrenia and substance use disorders. SchizophrBulL 2006;32(4):637-643.
50. Drake RE, Xie H, McHugo GJ, et al. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull. 2000; 26(2):441-449.
51. Green Al, Noordsy DL, Brunette MF, et al. Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Subst Abuse Treat. 2008;34(1):61-71.
52. Falk D, Wang XQ, Liu L, et al. Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials. Alcohol Clin ExpRes. 2010;34(12):2022-2034.
53. Schuckit MA, Tipp JE, Bucholz KK, et al. The life time rates of three major mood disorders and four major anxiety disorders in alcoholics and controls. Addiction. 1997;92(10):1289-1304.